Hepatitis B Virus Therapy
Findings from Bristol-Myers Squibb Company provide new insights into hepatitis B virus therapy
Published in Hepatitis Weekly, April 9th, 2007
Investigators publish new data in the report "Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present." According to recent research from the United States, "Entecavir (ETV) is a deoxyguanosine analog approved for use for the treatment of chronic infection with wild-type and lamivudine-resistant (LVDr) hepatitis B virus (HBV). In LVD-refractory patients, 1.0 mg ETV suppressed HBV DNA levels to below the level of detection by PCR (<300 copies/ml) in 21% and 34% of patients by Weeks 48 and 96, respectively."
"Prior studies showed that virologic...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2007-04-09)
More Articles from Hepatitis Weekly
- Hepatitis C Virus
XTL Announces the Completion of Phase I Study With XTL-6865 in Patients With Chronic Hepatitis C - Cancer Vaccines
Researchers at Hacettepe University, Department of Pediatric Hematology release new data on cancer vaccines - Gene Therapy
Research from Shaanxi Normal University, College of Life Sciences provides new data on gene therapy - Hepatitis B Virus Genetics
Reports summarize hepatitis B virus genetics study results from Peking Union Medical College, Medical College - Hepatitis B Virus Prognosis
Studies from Yonsei University, Institute of Gastroenterology provide new data on hepatitis B virus prognosis - Hepatitis B Virus Therapy
New research on hepatitis B virus therapy from St. Marianna University summarized - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
